Biogen Intangible Assets

Biogen (BIIB) currently reports a intangible assets of $14B as of June 2026. That compares with $9.5B in the prior-year period — up 42.8% year over year. Use the charts on this page to explore Biogen's intangible assets history and peer comparisons.

Biogen's intangible assets increased from $9.5B to $14B — a 42.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biogen reported $14B in intangible assets as of June 2026. That compares with $9.5B in the prior-year period — up 42.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $14B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biogen, and consider following BIIB for alerts when major investors trade the stock.

Biogen is classified in the Healthcare sector. On intangible assets, it currently shows $14B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIIB with unrelated industries.